{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:51:01Z","timestamp":1782791461058,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04099-1","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:01:57Z","timestamp":1718150517000},"page":"3617-3625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical value of adding Dapagliflozin in patients with nephrotic syndrome"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2007-7385","authenticated-orcid":false,"given":"Magdy","family":"ElSharkawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-8648","authenticated-orcid":false,"given":"Ahmed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mohyeldin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ElSayed","family":"Ghonamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0095-8721","authenticated-orcid":false,"given":"Nahla Mohamed","family":"Teama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"4","key":"4099_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TA et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"7654","key":"4099_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull RP, Goldsmith DJA (2008) Nephrotic syndrome in adults. BMJ 336(7654):1185\u20131189. https:\/\/doi.org\/10.1136\/bmj.39576.709711.80","journal-title":"BMJ"},{"issue":"15","key":"4099_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/nejmoa2024816","journal-title":"N Engl J Med"},{"issue":"24","key":"4099_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/nejmoa1811744","journal-title":"N Engl J Med"},{"key":"4099_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Judge P, Mayne KJ (2023) Empagliflozin in patients with Chronic kidney disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med."},{"key":"4099_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","author":"P Cassis","year":"2018","unstructured":"Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C et al (2018) SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.98720","journal-title":"JCI Insight."},{"issue":"1","key":"4099_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/CKJ\/SFAC189","volume":"16","author":"Z Kalay","year":"2023","unstructured":"Kalay Z, Sahin OE, Copur S, Danac\u0131 S, Ortiz A, Yau K et al (2023) SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J 16(1):52. https:\/\/doi.org\/10.1093\/CKJ\/SFAC189","journal-title":"Clin Kidney J"},{"issue":"9","key":"4099_CR8","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","volume":"37","author":"DC Wheeler","year":"2022","unstructured":"Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Houet FF (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dialysis Transplant. 37(9):1647\u20131656. https:\/\/doi.org\/10.1093\/ndt\/gfab335","journal-title":"Nephrol Dialysis Transplant."},{"issue":"1","key":"4099_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T et al (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215\u2013224. https:\/\/doi.org\/10.1016\/j.kint.2021.03.033","journal-title":"Kidney Int"},{"issue":"7","key":"4099_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","volume":"37","author":"WG Herrington","year":"2022","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2022) Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 37(7):1317\u20131329. https:\/\/doi.org\/10.1093\/ndt\/gfac040","journal-title":"Nephrol Dial Transplant"},{"key":"4099_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03508-1","author":"A Elkeraie","year":"2023","unstructured":"Elkeraie A, Zyada R, Elrggal ME, Elrggal M (2023) Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies. Eur J Clin Pharmacol. https:\/\/doi.org\/10.1007\/s00228-023-03508-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"19","key":"4099_CR12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y et al (2021) New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385(19):1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N Engl J Med"},{"issue":"7","key":"4099_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ et al (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8(7):582\u2013593. https:\/\/doi.org\/10.1016\/S2213-8587(20)30162-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4099_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071815","author":"J Boeckhaus","year":"2021","unstructured":"Boeckhaus J, Gross O (2021) Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, alport syndrome, and fsgs: a case series to better plan a large-scale study. Cells. https:\/\/doi.org\/10.3390\/cells10071815","journal-title":"Cells."},{"issue":"3","key":"4099_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ekir.2021.12.019","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Cui J, Fang X, Chen J, Yan W, Shenet Q et al (2022) Efficacy and safety of dapagliflozin in children with inherited Proteinuric kidney disease: a pilot study. Kidney Int Rep 7(3):638\u2013641. https:\/\/doi.org\/10.1016\/j.ekir.2021.12.019","journal-title":"Kidney Int Rep"},{"key":"4099_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1152\/ajprenal.00445.2017.-Focal","volume":"314","author":"H Rajasekeran","year":"2018","unstructured":"Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y et al (2018) Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Physiol Renal Physiol 314:412\u2013422. https:\/\/doi.org\/10.1152\/ajprenal.00445.2017.-Focal","journal-title":"Physiol Renal Physiol"},{"key":"4099_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091855","author":"N Oliva-Damaso","year":"2021","unstructured":"Oliva-Damaso N, Mora-Guti\u00e9rrez JM, Bomback AS (2021) Glomerular diseases in diabetic patients: implications for diagnosis and management. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10091855","journal-title":"J Clin Med."},{"issue":"14","key":"4099_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohl\u00e1vek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353\u20131368. https:\/\/doi.org\/10.1001\/jama.2020.1906","journal-title":"JAMA"},{"issue":"9","key":"4099_CR19","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116\u20132124. https:\/\/doi.org\/10.1111\/dom.14451","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"4099_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/a-0664-7583","volume":"128","author":"AM Ram\u00edrez-Rodr\u00edguez","year":"2020","unstructured":"Ram\u00edrez-Rodr\u00edguez AM, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E (2020) Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes 128(8):506\u2013511. https:\/\/doi.org\/10.1055\/a-0664-7583","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"4099_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jcte.2013.12.001","volume":"1","author":"A Napolitano","year":"2014","unstructured":"Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET et al (2014) Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. J Clin Transl Endocrinol. 1(1):3\u20138. https:\/\/doi.org\/10.1016\/j.jcte.2013.12.001","journal-title":"J Clin Transl Endocrinol."},{"issue":"10","key":"4099_CR22","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/S00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61(10):2098\u20132107. https:\/\/doi.org\/10.1007\/S00125-018-4669-0","journal-title":"Diabetologia"},{"issue":"1","key":"4099_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/dom.12779","volume":"19","author":"P Lundkvist","year":"2017","unstructured":"Lundkvist P, Sj\u00f6str\u00f6m CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW (2017) Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab 19(1):49\u201360. https:\/\/doi.org\/10.1111\/dom.12779","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"4099_CR24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/oby.20663","volume":"22","author":"HE Bays","year":"2014","unstructured":"Bays HE, Weinstein R, Law G, Canovatchel W (2014) Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 22(4):1042\u20131049. https:\/\/doi.org\/10.1002\/oby.20663","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"4099_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/17425255.2018.1541348","volume":"14","author":"S Filippas-Ntekouan","year":"2018","unstructured":"Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M (2018) SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol 14(11):1113\u20131121. https:\/\/doi.org\/10.1080\/17425255.2018.1541348","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"4099_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"H Storgaard","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, Gr\u00f8ndahl MF, Christensen MB, Knop FK et al (2016) Benefits and harms of sodium-glucose Co-transporter 2 inhibitors in patients with Type 2 diabetes: a systematic review and meta-analysis. PLoS One 11(11):e0166125. https:\/\/doi.org\/10.1371\/journal.pone.0166125","journal-title":"PLoS One"},{"key":"4099_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007165","author":"XL Zhang","year":"2018","unstructured":"Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA et al (2018) Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with Type 2 Diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.007165","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"4099_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","volume":"42","author":"TAS Halden","year":"2019","unstructured":"Halden TAS, Kvitne KE, Midtvedt K et al (2019) Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant Diabetes mellitus. Diabetes Care 42(6):1067\u20131074. https:\/\/doi.org\/10.2337\/dc19-0093","journal-title":"Diabetes Care"},{"issue":"3","key":"4099_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ajt.15223","volume":"19","author":"E Schwaiger","year":"2019","unstructured":"Schwaiger E, Burghart L, Signorini L et al (2019) Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 19(3):907\u2013919. https:\/\/doi.org\/10.1111\/ajt.15223","journal-title":"Am J Transplant"},{"issue":"10","key":"4099_CR30","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","volume":"51","author":"N Attallah","year":"2019","unstructured":"Attallah N, Yassine L (2019) Use of empagliflozin in recipients of kidney transplant: a report of 8 cases. Transplant Proc 51(10):3275\u20133280. https:\/\/doi.org\/10.1016\/j.transproceed.2019.05.023","journal-title":"Transplant Proc"},{"issue":"5","key":"4099_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1159\/000501854","volume":"44","author":"M Mahling","year":"2019","unstructured":"Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M (2019) Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 44(5):984\u2013992. https:\/\/doi.org\/10.1159\/000501854","journal-title":"Kidney Blood Press Res"},{"issue":"9","key":"4099_CR32","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","volume":"106","author":"JH Lim","year":"2022","unstructured":"Lim JH, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS et al (2022) The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation 106(9):e404\u2013e412. https:\/\/doi.org\/10.1097\/TP.0000000000004228","journal-title":"Transplantation"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04099-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:04:12Z","timestamp":1728489852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["4099"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04099-1","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}